Oragenics Valuation
| OGEN Stock | USD 1.44 0.06 4.35% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Oragenics holds a recent Real Value of $1.38 per share. The prevailing price of the company is $1.44. Our model determines the value of Oragenics from analyzing the company fundamentals such as Shares Owned By Institutions of 1.01 %, shares outstanding of 822.93 K, and Return On Equity of -7.48 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Oragenics' valuation include:
Price Book 8.6065 | Enterprise Value | Enterprise Value Ebitda 0.2113 | Price Sales 89.2791 | Enterprise Value Revenue 105.8267 |
Overvalued
Today
Please note that Oragenics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Oragenics is based on 3 months time horizon. Increasing Oragenics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Oragenics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Oragenics Stock. However, Oragenics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.44 | Real 1.38 | Target 1.0 | Hype 1.44 | Naive 1.85 |
The intrinsic value of Oragenics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Oragenics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Oragenics helps investors to forecast how Oragenics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Oragenics more accurately as focusing exclusively on Oragenics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Oragenics' intrinsic value based on its ongoing forecasts of Oragenics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Oragenics' closest peers.
Oragenics Cash |
|
Oragenics Valuation Trend
Knowing Oragenics' actual value is paramount for traders when making sound investment determinations. Using both Oragenics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Oragenics Total Value Analysis
Oragenics is now forecasted to have valuation of 318.32 K with market capitalization of 1.19 M, debt of 328.53 K, and cash on hands of 17.87 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Oragenics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
318.32 K | 1.19 M | 328.53 K | 17.87 M |
Oragenics Asset Utilization
One of the ways to look at asset utilization of Oragenics is to check how much profit was generated for every dollar of assets it reports. Oragenics holds a negative application of assets of -1.71 pct., losing $0.0171 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Oragenics shows how discouraging it operates for each dollar spent on its assets.Oragenics Ownership Allocation
Oragenics holds 12.11 pct. of its outstanding shares held by insiders and 1.01 pct. owned by third-party entities.Oragenics Profitability Analysis
Net Loss for the year was (10.57 M) with loss before overhead, payroll, taxes, and interest of (3.79 M).About Oragenics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Oragenics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Oragenics based exclusively on its fundamental and basic technical indicators. By analyzing Oragenics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Oragenics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Oragenics. We calculate exposure to Oragenics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Oragenics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -24.7 K | -23.4 K | |
| Pretax Profit Margin | (630.87) | (599.33) | |
| Operating Profit Margin | (638.48) | (606.55) | |
| Net Loss | (630.87) | (599.33) | |
| Gross Profit Margin | (471.96) | (448.37) |
Oragenics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 6.6 M |
Oragenics Current Valuation Indicators
Oragenics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Oragenics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Oragenics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Oragenics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Oragenics' worth.When determining whether Oragenics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oragenics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oragenics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oragenics Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oragenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oragenics. If investors know Oragenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oragenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oragenics is measured differently than its book value, which is the value of Oragenics that is recorded on the company's balance sheet. Investors also form their own opinion of Oragenics' value that differs from its market value or its book value, called intrinsic value, which is Oragenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oragenics' market value can be influenced by many factors that don't directly affect Oragenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oragenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oragenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oragenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.